News

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...
What Happened? Shares of game engine maker Unity (NYSE:U) fell 3.5% in the afternoon session after analysts at BTIG downgraded the stock from "Neutral" to "Sell" and set a new price target of $25.00.
Investing.com -- In a note to clients on Wednesday, BTIG downgraded Unity shares to Sell from Neutral, arguing that the stock ...
Elastic is well-positioned to benefit from AI trends, with its leadership in vector search and growing cloud revenue likely ...
Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...
Palantir's Q2 revenue to hit $939 million, driven by AIP growth and strong U.S. commercial gains. Read why I rate PLTR stock ...
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...
Beyond Snapdeal, Gurugram-based AceVector operates Unicommerce, a software-as-a-service platform, and Stellar Brands, a ...
Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on ...